Posts Tagged ‘off-label prescribing’

Death of 7-year old prompts Florida officials to ask FDA to forbid allowing foster kids as guinea pigs in drug trials

Monday, July 19th, 2010

Pharmalot
By Ed Silverman
July 19, 2010

Last year, a 7-year-old foster boy named Gabriel Myers committed suicide in Florida and, after reams of publicity and hand-wringing over the use of psychotropic medications in such children, a state task force recommended, among other things, that children never be allowed to participate in a clinical trial designed to evaluate new psychotropic meds or whether such drugs approved for adults should be given to children.

The move was prompted, in part, because a Florida psychiatrist, Sohail Punjwani, who treated the boy before he committed suicide, received an FDA warning letter for failing “to protect the rights, safety and welfare” of children enrolled in clinical trials (back story). Before the suicide, the psychiatrist prescribed to kids several drugs, some of which weren’t approved by the FDA for use on children and had been linked to dangerous side effects, including an increased risk of suicide among children (back story).

As part of the follow-up, George Sheldon, who head’s Florida’s Department of Children and Families, wrote FDA commish Margaret Hamburg for info about any foster children who might have participated in clinical trials for psychotropic meds (read the letter) and asked the FDA to forbid foster kids from participating in these trials. Last month, the agency wrote back to say the agency does not agree with a “blanket prohibition” on enrolling foster children. Why? Such a policy fails to account for the greater risk of off-label prescribing and research involving children can yield benefits that cannot be obtained by tracking usage in adults, Jill Warner, acting associate commissioner for the FDA’s Special Medical Programs, wrote back (see here). Drugmakers, by the way, also have something at stake – they receive an extra six months of marketing exclusivity in return for having conducted the pediatric trials.

We asked Florida officials if they are rethinking their position. The answer? No way. The state is resolute.

Read entire article:  http://www.pharmalot.com/2010/07/florida-tells-fda-no-children-in-psychotropic-trials/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot

« Return to news items


  • Share/Bookmark

Killing You with Drugs: Legally—Pharma’s attempts to bury increasing # of studies linking psychiatric drugs to suicide

Thursday, April 15th, 2010

The Market Oracle
By Michael Stathis
April 15, 2010

Is there any reason why Pfizer shares are down today?

Just yesterday, shares were trading at ~ $17.30. Today, with the DJIA up by 0.7%, Pfizer is down by nearly 1%.

A clue to this sell-off MIGHT be due to the anticipation by investors of increasing pressure to change the way drugs are prescribed. This could also trigger several lawsuits down the road.

Recently, another study was published in the Journal of the American Medical Association discussing elevated suicide risks associated with the use of anticonvulsant drugs. Anticonvulsants have been approved by the FDA for people diagnosed with epilepsy.

Of course, this is not the first study showing anticonvulsants raised the risk of suicide.

In 2008, the FDA required all anticonvulsant drugs to have a warning label that disclosed a two-fold increased risk of suicide. However, warning labels are rarely effective. They simply enable drug companies to continue to sell what many experts feel to be dangerous drugs, while having the safeguard of a disclaimer.

When patients receive a prescription for a drug to address a medical condition, they assume it’s a safe drug; otherwise, it wouldn’t be approved for use. And their doctor certainly wouldn’t prescribe it if it weren’t safe, would he?

According to DEA and FDA regulations, physicians are free to prescribe any drug for any condition they see fit, known as off-label use. As a result of off-label usage, anticonvulsants are prescribed for many different medical conditions like bipolar disorder, pain and migraine headaches. As you might imagine, in some cases, off-label use has accounted for a big chunk of drug sales.

The class of drugs prescribed most by physicians for off-label uses are the antipsychotics (Prozac, Xanax, Zyprexa, etc). The FDA has approved these drugs to treat a variety of neurologic conditions such as depression and bipolar disease. However, drug companies have used many methods to get physicians to prescribe them for a wide range of off-label uses.

Read entire article:  http://www.marketoracle.co.uk/Article18652.html

« Return to news items


  • Share/Bookmark

Florida looks to curb drugging kids with bill named after 7-yr-old who hanged himself on prescribed drug cocktail

Tuesday, April 13th, 2010

CBS4.com
By Lisa Cilli
April 13, 2010

Florida lawmakers are scheduled to discuss a measure Tuesday designed to curb the prescription of mental-health drugs to children in state care. Senate Bill 2718, also known as the Gabriel Myers Bill, would allow officials to more closely monitor the powerful psychiatric drugs dispensed to Florida foster care children.

The proposal is largely based on the findings of a task force formed after Gabriel locked himself in a bathroom and hung himself with a shower cord last April in his Margate foster home. Gabriel was on Seroquel, used to treat bipolar disorder, and other psychiatric drugs linked by federal regulators to potentially dangerous side effects, including suicide, but the risks may not have been adequately communicated to his foster parents. The drugs are not approved for use by young children. But doctors often prescribe them ‘off-label,’ for purposes for which the drugs have not been approved.

Sen. Ronda Storms (R)-Brandon, who filed the bill, said prescribed drugs have replaced talk therapy and are over-prescribed to subdue unruly children.

The proposed law would require the state Department of Children and Families to assign volunteer guardians to oversee each child’s mental health care. It prohibits foster children from being the subject of clinical drug trials and raises the age at which children are allowed to take these drugs from 6 to 11 in many cases.

Read entire article:  http://cbs4.com/local/florida.legislators.legislation.2.1629212.html

« Return to news items


  • Share/Bookmark

“Drugged Warriors: Sharp Rise in U.S. Military Psychiatric Drug Use and Suicides” by Psychologist Bruce Levine

Friday, April 2nd, 2010

Sharp Rise in U. S. Military Psychiatric Drug Use and Suicides

CounterPunch
By Bruce E. Levine
April 2, 2010

One in six service members is now taking at least one psychiatric drug, according to the Navy Times, with many soldiers taking “drug cocktail” combinations. Soldiers and military healthcare providers told the Military Times that psychiatric drugs are “being prescribed, consumed, shared and traded in combat zones.”

The Navy Times reporters Andrew Tilghman and Brendan McGarry also noted that there has been a large increase in military suicides. From 2001 to 2009, the Army’s official suicide rate increased from 9 per 100,000 soldiers to 23 per 100,000. During that same period, the Marine Corps suicide rate increased from 16.7 per 100,000 soldiers to 24 per 100,000.

A Military Times investigation of records obtained from the Defense Logistics Agency revealed that the DLA spent $1.1 billion on psychiatric and pain medications from 2001 to 2009, and that there was a 76 percent increase in psychiatric drugs. DLA records show:

• Antipsychotic drugs spiked most dramatically — orders jumping by more than 200 percent.

• Orders for anti-anxiety drugs and sleeping pills such as Valium and Ambien increased 170 percent.

• Orders for antiepileptic drugs (also known as anticonvulsants) such as Depakote, routinely used as psychiatric medications, increased 70 percent.

• Antidepressants showed a 40 percent increase.

Investigators found that antipsychotic and antiepileptic drugs, approved for bipolar disorder and schizophrenia, are now commonly used to treat post-traumatic stress disorder (PTSD) symptoms such as nightmares, nervousness, and anger outbursts. The use of antipsychotic drugs for non-psychotic conditions such as PTSD is called “off-label” prescribing. The general public is also subject to off-label prescribing, which is considered legal.

Read entire article:  http://www.counterpunch.org/levine04022010.html

« Return to news items


  • Share/Bookmark

After 7-Year-Old Gabriel Myers’ Suicide (on 3 psychiatric drugs) Florida Bill Looks to Tighten Access to Psychiatric Drugs

Thursday, March 18th, 2010

CBSNews.com
By Edecio Martinez
March 17, 2010

The apparent suicide of 7-year-old boy Gabriel Myers, who was taking several psychiatric medications, has led to the introduction of a bill in the Florida legislature, which would assure that powerful mental health drugs dispensed to Florida foster care children would be more closely monitored.

The proposal is largely based on the findings of a task force formed after Gabriel locked himself in a bathroom and hung himself with a shower cord last April.

Gabriel was on Seroquel – used to treat bipolar disorder – and other psychiatric drugs linked by federal regulators to potentially dangerous side effects, including suicide, but the risks may not have been adequately communicated to his foster parents.

The drugs are not approved for use by young children. But doctors often prescribe them ‘off-label,’ for purposes for which the drugs have not been approved.

Sen. Ronda Storms said prescribed drugs have replaced talk therapy and are over-prescribed to subdue unruly children. The measure would require an independent review before psychiatric drugs can be administered to children 10 or younger.

Read entire article:  http://www.cbsnews.com/8301-504083_162-20000546-504083.html

« Return to news items


  • Share/Bookmark

Eli Lilly to pay $24 million in Utah Attorney General’s Zyprexa lawsuit/AG says “we want their bad conduct to stop”

Thursday, November 12th, 2009

Geoff Leisik
Deseret News
November 11, 2009

Pharmaceutical giant Eli Lilly and Co. has agreed to pay $24 million to settle a lawsuit filed by the Utah Attorney General’s Office.

Attorney General Mark Shurtleff sued the company after a nearly four-year investigation revealed that Lilly concealed its knowledge of significant weight gain and obesity associated with the anti-psychotic medication Zyprexa. Investigators also showed that Lilly’s sales representatives illegally promoted the drug for uses not approved by the U.S. Food and Drug Administration.

“We’re not just asking them for money. We want their bad conduct to stop,” Shurtleff said Wednesday while announcing the settlement.

“As part of the settlement agreement, there are corporate integrity responsibilities and remedial provisions that will continue to be monitored by the court to stop (Lilly’s) harmful behavior.”

Zyprexa is approved for the treatment of schizophrenia and certain types of bipolar disorder in adults. But authorities say that in 1999, Lilly’s marketing arm that focuses on doctors who treat the elderly began encouraging physicians to prescribe the drug for dementia, Alzheimer’s disease, agitation, aggression, hostility, depression and generalized sleep disorder without prior FDA approval. Lilly also trained its sales teams to avoid discussions with health-care professionals about the weight gain side effect, investigators said.

Read entire article: http://www.deseretnews.com/article/705343716/Firm-to-pay-Utah-24M-in-settlement.html

« Return to news items


  • Share/Bookmark